ANKE BIO(SZ:300009)2022-12-04 07:02R&D Progress - The company has two specifications for recombinant human growth hormone water injection: 4IU/1.33mg/1ml and 10IU/3.33mg/1ml, with plans to increase product specifications based on market demand [3] - HER-2 monoclonal antibody is currently in Phase III clinical trials, with patient enrollment completed and data preparation underway for production application [3] - The recombinant PD-1 humanized monoclonal antibody is in Phase I/II clinical trials, while VEGF monoclonal antibody is undergoing Phase III clinical trials [3] - The PEG-recombinant human growth hormone injection has completed clinical trials and is currently undergoing production line modifications in preparation for production application [3] Market Development - The company aims to strengthen its domestic forensic DNA business while actively expanding into international forensic DNA markets [4] - Future plans include entering the clinical DNA testing and rapid DNA testing for crime scenes to identify new profit growth points [4] Market Demand - The market for recombinant human growth hormone is experiencing steady growth due to increasing demand, heightened awareness among families of children with growth deficiencies, a rise in pediatricians, improved economic capacity, and deeper marketing channels [4]